Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
251
Completed, industry sponsors, Immunology and inflammation, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed251
251 trials
Showing 1 to 25, recently updated first.
LEO PharmaIndustry
NCT06013969 · 42 participants · Start Oct 22, 2023 · Primary completion May 13, 2026
Drug: Spesolimab · For: Generalized Pustular Psoriasis
Sites: Irvine, California; Fargo, North Dakota; Liverpool, Australia · 35 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07006792 · 233 participants · Start Jun 16, 2025 · Primary completion May 14, 2026
Drug: Lebrikizumab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Litchfield Park, Arizona; Phoenix, Arizona · 66 sites in all
- Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03747939 · 310 participants · Start Dec 31, 2018 · Primary completion Dec 19, 2022
Drug: Apremilast (CC-10004) · For: Arthritis, Psoriatic
Sites: Mesa, Arizona; Covina, California; Encino, California · 114 sites in all
- A Study of Baricitinib in Participants With Rheumatoid ArthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04086745 · 1,050 participants · Start Feb 14, 2020 · Primary completion May 19, 2025
Drug: Baricitinib; TNF Inhibitor · For: Rheumatoid Arthritis
Sites: Chandler, Arizona; Mesa, Arizona; Paradise Valley, Arizona · 119 sites in all
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03915964 · 2,659 participants · Start Apr 25, 2019 · Primary completion May 28, 2025
Drug: Baricitinib; TNF Inhibitor · For: Rheumatoid Arthritis
Sites: Flagstaff, Arizona; Gilbert, Arizona; Glendale, Arizona · 261 sites in all
- A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis PatientsCompleted
Galderma R&DIndustry
NCT06357221 · 46 participants · Start Apr 8, 2024 · Primary completion Jul 18, 2024
Drug: Cetaphil · For: Plaque Psoriasis; Psoriasis
Sites: Columbus, Georgia; Douglasville, Georgia; High Point, North Carolina
- A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community SettingPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05701995 · 180 participants · Start Jan 31, 2023 · Primary completion Aug 23, 2024
Drug: Deucravacitinib · For: Psoriasis
Sites: Phoenix, Arizona; Scottsdale, Arizona; North Little Rock, Arkansas · 38 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05590585 · 124 participants · Start Jan 11, 2023 · Primary completion Nov 14, 2024
Drug: dupilumab · For: Moderate-to-Severe Atopic Dermatitis; Atopic Eczema
Sites: Birmingham, Alabama; Montgomery, Alabama; Fremont, California · 30 sites in all
Eisai Korea Inc.Eisai
NCT06625242 · 118 participants · Start Oct 22, 2024 · Primary completion Jan 21, 2026
Drug: Filgotinib Maleate · For: Rheumatoid Arthritis
Sites: Anyang-si, South Korea; Busan, South Korea; Daegu, South Korea · 15 sites in all
GlaxoSmithKlineGSK (GSK)
NCT04908865 · 67 participants · Start Oct 21, 2021 · Primary completion May 23, 2024
Drug: Belimumab; Standard therapy · For: Systemic Lupus Erythematosus
Sites: Beijing, China; Changchun, China; Changsha, China · 9 sites in all
- Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body WeightPivotal-lookingCompleted
LEO PharmaIndustry
NCT04306315 · 385 participants · Start Jul 21, 2022 · Primary completion Aug 25, 2025
Drug: Brodalumab · For: Psoriasis Vulgaris
Sites: Brussels, Belgium; Ham-sur-Heure-Nalinnes, Belgium; Leuven, Belgium · 81 sites in all
- Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic SyndromePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03440736 · 781 participants · Start Feb 28, 2018 · Primary completion Nov 30, 2021
Drug: Secukinumab · For: Psoriasis; Metabolic Syndrome
Sites: Langenau, Germany; Munich, Germany; Darmstadt, Germany · 75 sites in all
AbbVieAbbVie (ABBV)
NCT06346288 · 10 participants · Start Apr 24, 2024 · Primary completion Feb 5, 2026
Drug: Risankizumab · For: Inflammatory Bowel Disease
Sites: Chapel Hill, North Carolina; Houston, Texas; Jerusalem, Israel
- A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT06333860 · 393 participants · Start May 10, 2024 · Primary completion Mar 19, 2026
Drug: Risankizumab; Deucravacitinib · For: Moderate Plaque Psoriasis
Sites: Birmingham, Alabama; Glendale, Arizona; Scottsdale, Arizona · 88 sites in all
Bausch Health Americas, Inc.Industry
NCT03988439 · 16 participants · Start Mar 24, 2021 · Primary completion Feb 6, 2026
Drug: IDP-118 Lotion · For: Psoriasis
Sites: Doral, Florida; Miami, Florida; Louisville, Kentucky · 9 sites in all
- Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp PsoriasisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT05969223 · 214 participants · Start Aug 10, 2023 · Primary completion Jan 22, 2025
Drug: Risankizumab; Placebo for Risankizumab · For: Genital Psoriasis; Scalp Psoriasis
Sites: Phoenix, Arizona; Tucson, Arizona; Encino, California · 38 sites in all
- Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp PsoriasisPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05478499 · 154 participants · Start Oct 6, 2022 · Primary completion Jan 11, 2024
Drug: Deucravacitinib · For: Psoriasis
Sites: Hot Springs, Arkansas; Indianapolis, Indiana; Louisville, Kentucky · 29 sites in all
SanofiSanofi (SNY)
NCT04447417 · 52 participants · Start Jul 16, 2020 · Primary completion Jun 17, 2021
Drug: Dupilumab SAR231893 · For: Atopic Dermatitis
Sites: Denver, Colorado; Montreal, Canada
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05029921 · 182 participants · Start Dec 10, 2021 · Primary completion May 18, 2025
Drug: Ustekinumab · For: Crohn Disease
Sites: Beijing, China; Changsha, China; Changzhou, China · 29 sites in all
- SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04033367 · 188 participants · Start Aug 22, 2019 · Primary completion Oct 6, 2021
Drug: Dupilumab; Placebo · For: Atopic Dermatitis
Sites: North Little Rock, Arkansas; Redwood City, California; Rolling Hills Estates, California · 42 sites in all
SanofiSanofi (SNY)
NCT04823130 · 54 participants · Start Apr 22, 2021 · Primary completion Jun 30, 2022
Drug: Dupilumab (SAR231893) · For: Dermatitis Atopic
Sites: Miami, Florida; East Windsor, New Jersey; Münster, Germany
SanofiSanofi (SNY)
NCT05624112 · 44 participants · Start Nov 25, 2022 · Primary completion Jan 25, 2024
Drug: Dupilumab · For: Atopic Dermatitis; Dermatitis Atopic
Sites: Guangzhou, China
- Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic DermatitisCompleted
SanofiSanofi (SNY)
NCT04718870 · 41 participants · Start Feb 19, 2021 · Primary completion Sep 7, 2022
Drug: Dupilumab SAR231893 · For: Dermatitis Atopic
Sites: Los Angeles, California; Denver, Colorado; Sheffield, United Kingdom
Eli Lilly and CompanyEli Lilly (LLY)
NCT05855967 · 250 participants · Start Jun 27, 2023 · Primary completion Aug 8, 2024
Drug: Ixekizumab · For: Plaque Psoriasis; Psoriatic Arthritis
Sites: Vizag, India; Raipur, India; Ahmedabad, India · 14 sites in all
- A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT05507580 · 461 participants · Start May 29, 2023 · Primary completion Jul 11, 2024
Drug: Upadacitinib · For: Atopic Dermatitis
Sites: Darlinghurst, Australia; Kogarah, Australia; Woolloongabba, Australia · 106 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.